Genmab — Maj 2019
-
@Sukkeralf: Super indlæg...mange tak
-
Godt indlæg Sukker.
-
Mangler spørgsmål til Q&A. Skyd nu bare løs.
-
Super Sukker.
-
Tilslutter mig også rosen til sukkeralf. Vi skal blot være obs på at ofa kan komme til at betyde en hel del på relaltiv kort bane i RRMS. Vi har et multi $bn marked i MS og royalty er 12% til Genmab. Altså kunne der meget snart (kort årrække)tilflyde Genmab over 1bn DKK årligt herfra.
-
Tak for sammenfatningen sukker. mht partneraftale (fra CC): "So we have a lot of potential for that program for partnering. We think we want to see data. We expect data for the CD3xCD20 before or at the ASH meeting this year." Så det bliver næppe før sidst på året, at vi ser noget på den front.
-
-
Speaking on Regeneron's quarterly earnings call, CSO George Yancopoulos disclosed two patient deaths in the company's Phase I study combining its in-house PD-1 antibody Libtayo (cemiplimab, formerly known as RG2810) with bispecific antibody RG1979.
-
ancopoulos told analysts that "we observed enhanced cytokine release syndrome, or CRS … including unfortunately two fatalities potentially related to the CRS." He added that "we plan to modify the dosing regimen with the goal of minimising toxicity while potentially capturing the potentially increased activity."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind